-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology ADCC Platform: Leading a New Chapter in Tumor Immunotherapy
Author:
InnoModels
Release time:
2024-05-09
In the current field of biomedical research, tumor immunotherapy is undoubtedly one of the most promising therapeutic means. Among them, antibody-dependent cytotoxicity (ADCC), as an important immune mechanism, plays a pivotal role in tumor treatment. The ADCC platform built by InnoModels Biotechnology is based on this mechanism and provides powerful in vitro experimental support for tumor immunotherapy research.
1、ADCC mechanism and tumor immunotherapy
ADCC is an antibody-mediated immune cell killing mechanism. When antibodies bind to antigens on the surface of tumor cells, these antibodies can bind to Fc receptors on the surface of immune cells (e.g., natural killer cells, NK cells), thereby activating these immune cells and causing them to attack tumor cells. In this process, NK cells, as key players, are responsible for attacking those tumor cells labeled by antibodies.

2. Characteristics of InnoModels Biotechnology ADCC platform
(1) Diversity of target cell choices: InnoModels' ADCC platform provides a variety of target cell choices, including tumor cell lines, primary tumor cells and genetically engineered cell lines. These target cell choices not only meet a wide range of research and testing needs, but also more realistically simulate the biological environment, providing closer to real experimental conditions for tumor immunotherapy research.
2) Abundance of effector cell sources: The platform also demonstrates its flexibility in the selection of effector cells. In addition to commercially available PBMC (peripheral blood mononuclear cells), there are also clinical patient-derived PBMC and the NK92 cell line, which is specifically designed for NK cell research. These diverse sources of effector cells allow researchers to choose the most appropriate cell type for specific research needs.
3) High-precision detection and analysis tools: The platform uses high-precision technologies such as flow assay, which can accurately distinguish between effector cells and target cells, providing accurate data support for research. At the same time, through flow technology, it can also accurately calculate the proportion of apoptotic cells, so as to intuitively assess the effect of ADCC.
3、Significance of the ADCC platform of InnoModels Biotechnology
InnoModels' ADCC platform not only provides powerful in vitro experimental support for tumor immunotherapy research, but also promotes the research progress in this field. Through this platform, researchers can gain a deeper understanding of the role of ADCC mechanism in tumor immunotherapy and provide theoretical support and practical guidance for the development of more effective tumor immunotherapy methods.
In conclusion, with its diverse selection of target and effector cells and high-precision detection and analysis methods, the ADCC platform of InnoModels Biotechnology has opened up a new path for tumor immunotherapy research. With the deepening of the research, we have reason to believe that this platform will play an even more important role in tumor immunotherapy in the future.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd